Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
24. August 2023 09:00 ET
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available...
Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel
19. Januar 2021 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03
23. Dezember 2020 07:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
Tarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell 3000® Index and Russell 2000® Index
21. Dezember 2020 07:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
13. November 2020 19:35 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus” NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver...
Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares
20. Oktober 2020 16:05 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of...
Tarsus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering
15. Oktober 2020 20:35 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc., (“Tarsus”) a late clinical-stage biopharmaceutical company focused on the development and commercialization of...